Aurora Cannabis (ACB) reported its third-quarter earnings on May 14. Since then, the stock has mainly moved sideways. Let’s look at how analysts’ ratings and target price have changed since the earnings release.
Sign up for Bagels & Stox, our witty take on the top market and investment news, straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.
As of May 15, analysts’ consensus rating on the stock was a “buy. ” Four analysts have a “strong buy” recommendation on the stock—compared to three analysts in the previous period. Currently, six analysts have a “buy” recommendation on the stock—compared to five analysts in the previous period. In May, two analysts maintained a “hold” rating, while one analyst maintained a “sell” rating on the stock.
Aurora Cannabis’ current consensus target price was 14.5 Canadian dollars, which increased from 13.8 Canadian dollars in the previous period. The median target price on the stock is 15 Canadian dollars.
Aurora Cannabis closed at 11.7 Canadian dollars on May 15 with a potential upside of 24% from the price convergence. The Horizons Marijuana Life Sciences ETF (HMMJ) closed at 20.2 Canadian dollars with a daily gain of 0.7%.